Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
The companies will identify and optimize novel CRISPR proteins owned by Mammoth, and then license those proteins to Horizon for use in engineered cell lines.
The firm said it plans to sign between five and 10 additional biopharma collaborations in fiscal year 2020, some with milestone and royalty payment structures.
